Mariëlle van Aalst1, Charlotte Marieke Nelen1, Abraham Goorhuis1, Cornelis Stijnis1, Martin Peter Grobusch2. 1. Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Academic Medical Center, University of Amsterdam, Meibergdreef 9, DD1100 Amsterdam, The Netherlands. 2. Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Academic Medical Center, University of Amsterdam, Meibergdreef 9, DD1100 Amsterdam, The Netherlands. Electronic address: m.p.grobusch@amc.uva.nl.
Abstract
BACKGROUND: The acute phase of chikungunya is well documented; less so are its long-term effects. This systematic literature review provides an overview of the currently available data. METHODS: We performed an electronic search in PubMed/Medline and checked reference lists. We included studies in English on long-term sequelae of chikungunya in adults and on long-term sequelae of congenital infection from 2000 to 2016. Case reports, reviews and studies with a follow-up shorter than 6 weeks were excluded. RESULTS: In total, 37 studies were included; with follow-up periods ranging from 1.5 to 72 months. Most studies were questionnaire-based studies only, in which clinical diagnoses such as arthritis, alopecia and depression were mostly recorded without professional verification. Persisting arthralgia/arthritis (arthralgia/joint stiffness plus joint swelling) was the most frequent problem encountered. Further frequently mentioned sequelae were alopecia and depression. Quality of life was reduced in many for months to years after the acute phase of chikungunya. Female gender, older age, some co-morbidities and the severity of the acute phase were associated with persistent arthralgia. Congenital infection was associated with neurocognitive dysfunctioning in early childhood. CONCLUSION: Chikungunya leads to (self-perceived) long-term sequelae in a considerable proportion of patients, impacting significantly on quality of life. Long-term chikungunya sequelae must be taken into account when dealing with this disease because of its important effect on public and individual health. Prospective large-scale, long-term studies with objective assessment of signs and symptoms attributed to the disease are needed to optimally quantify and qualify these problems.
BACKGROUND: The acute phase of chikungunya is well documented; less so are its long-term effects. This systematic literature review provides an overview of the currently available data. METHODS: We performed an electronic search in PubMed/Medline and checked reference lists. We included studies in English on long-term sequelae of chikungunya in adults and on long-term sequelae of congenital infection from 2000 to 2016. Case reports, reviews and studies with a follow-up shorter than 6 weeks were excluded. RESULTS: In total, 37 studies were included; with follow-up periods ranging from 1.5 to 72 months. Most studies were questionnaire-based studies only, in which clinical diagnoses such as arthritis, alopecia and depression were mostly recorded without professional verification. Persisting arthralgia/arthritis (arthralgia/joint stiffness plus joint swelling) was the most frequent problem encountered. Further frequently mentioned sequelae were alopecia and depression. Quality of life was reduced in many for months to years after the acute phase of chikungunya. Female gender, older age, some co-morbidities and the severity of the acute phase were associated with persistent arthralgia. Congenital infection was associated with neurocognitive dysfunctioning in early childhood. CONCLUSION:Chikungunya leads to (self-perceived) long-term sequelae in a considerable proportion of patients, impacting significantly on quality of life. Long-term chikungunya sequelae must be taken into account when dealing with this disease because of its important effect on public and individual health. Prospective large-scale, long-term studies with objective assessment of signs and symptoms attributed to the disease are needed to optimally quantify and qualify these problems.
Authors: Nurgun Kose; Julie M Fox; Gopal Sapparapu; Robin Bombardi; Rashika N Tennekoon; A Dharshan de Silva; Sayda M Elbashir; Matthew A Theisen; Elisabeth Humphris-Narayanan; Giuseppe Ciaramella; Sunny Himansu; Michael S Diamond; James E Crowe Journal: Sci Immunol Date: 2019-05-17
Authors: Alfonso J Rodriguez-Morales; Victor Manuel Restrepo-Posada; Nathalia Acevedo-Escalante; Esteban David Rodríguez-Muñoz; Manuela Valencia-Marín; Juan D Castrillón-Spitia; José J Londoño; Hector D Bedoya-Rendón; Javier de Jesús Cárdenas-Pérez; Jaime A Cardona-Ospina; Guillermo J Lagos-Grisales Journal: Rheumatol Int Date: 2017-08-21 Impact factor: 2.631
Authors: Ivan Delgado-Enciso; Brenda Paz-Michel; Valery Melnikov; Jose Guzman-Esquivel; Francisco Espinoza-Gomez; Alejandro D Soriano-Hernandez; Iram P Rodriguez-Sanchez; Margarita L Martinez-Fierro; Gabriel Ceja-Espiritu; Bertha A Olmedo-Buenrostro; Hector R Galvan-Salazar; Osiris G Delgado-Enciso; Josuel Delgado-Enciso; Uriel A Lopez-Lemus; Daniel A Montes-Galindo Journal: Exp Ther Med Date: 2017-12-21 Impact factor: 2.447
Authors: Hilary Bower; Mubarak El Karsany; Abd Alhadi Adam Hussein Adam; Mubarak Ibrahim Idriss; Ma'aaza Abasher Alzain; Mohamed Elamin Ahmed Alfakiyousif; Rehab Mohamed; Iman Mahmoud; Omer Albadri; Suha Abdulaziz Alnour Mahmoud; Orwa Ibrahim Abdalla; Mawahib Eldigail; Nuha Elagib; Ulrike Arnold; Bernardo Gutierrez; Oliver G Pybus; Daniel P Carter; Steven T Pullan; Shevin T Jacob; Tajeldin Mohammedein Abdallah; Benedict Gannon; Tom E Fletcher Journal: PLoS Negl Trop Dis Date: 2021-04-30
Authors: Maira Sant Anna Genaro; Micheli Said de Marchi; Matheus Yung Perin; Isabelle Silva Cossô; Renata Dezengrini Slhessarenko Journal: Am J Trop Med Hyg Date: 2020-11 Impact factor: 2.345